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Abstract: 
Liver resection remains the cornerstone of curative treatment for hepatocellular carcinoma and 
colorectal cancer liver metastases. Its success is dependent upon the extent of resection achieved. 
To this end, intra-operative imaging techniques have been experimented with to aid the surgeon. 
Fluorescence guided surgery (FGS) utilises the properties of near infrared light emitting molecules to 
identify malignant tissue, enabling the surgeon to maximise resection of diseased tissue and 
minimise collateral damage. Data from early trials showed increased superficial lesion detection 
when using fluorescence to guide liver resection. However, with far greater tissue penetration, intra-
operative ultrasound (IOUS) remains the gold-standard intra-operative imaging modality. 
Subsequent trials have shown that the concomitant use of both FGS and IOUS may increase tumour 
detection rates intra-operatively. This review provides a comprehensive analysis of the most 
compelling evidence regarding fluorescence in hepatobiliary surgery and addresses the challenges 
faced introducing it into common practice. 
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Can intra-operative fluorescence play a significant role in 
Hepatobiliary surgery? 
Principles of live fluorescence in oncological surgery  
Surgical resection remains the cornerstone of curative treatment for solid tumours. Its success is 
dependent upon the extent of resection achieved. The level of invasion by malignant tissue is 
assessed pre-operatively using imaging techniques such as computed tomography (CT) and magnetic 
resonant imaging (MRI). This allows staging of the disease and provides the surgeon with a blueprint 
of the local anatomy. Yet the pre-operative assessment often does not tell the whole story. Intra-
operatively, the surgeon uses vision and palpation to assess the extent of tumour invasion and 
resects tissue accordingly. A trade-off occurs between removing malignant tissue and preserving 
vital structures, the relationship between the two often only becomes apparent during the 
procedure. Over the last decade, intra-operative imaging techniques have been experimented with 
to aid the surgeon maximise resection of diseased tissue and minimise collateral damage. 
 
Fluorescence describes the phenomenon by which a molecule absorbs light of a particular wave-
length (excitation) and emits it at a longer wave-length (emission) (1). Light within the visible 
spectrum resides between wave-lengths of 350-740nm and cannot penetrate tissue. However, near 
infra-red light (NIR) has wave-lengths between 750-1000nm and is able to penetrate tissue up to 10 
mm in depth (1). To apply this in oncological surgery, a fluorescent marker taken up by malignant 
tissue is required. Non-specific markers, such as indocyanin-green (ICG) are the workhorses of 
fluorescence guided surgery (FGS) but specific fluorescent markers, guided by molecular targets are 
being developed. When malignant tissue (having taken up the fluorescent marker) is exposed to NIR 
light, it re-emits it. This is detected by a NIR camera system and images are merged with the white 
light images of the surgical field (Figure 1). The resulting images display the tumour in bright lights 
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compared with the surrounding healthy tissue. Not only are structures on the surface highlighted, 
but those up to 10mm in depth are also revealed. Theoretically, the advantages of this aiding 
resection of diseased tissue, whilst preserving healthy structures is evident, the question is whether 
it translates to improved patient outcomes.  
(Insert figure 1) (2) 
 
Value of the R0 resection in hepatobiliary malignancy 
Hepatocellular Carcinoma (HCC) is a leading cause of cancer related death worldwide. Although only 
the 6
th
 most common malignancy, it has the second highest mortality, resulting in over 700,000 
deaths annually (3). The highest incidence rates are in China, Japan and throughout Africa, with 
incidence in Europe relatively low at 6 per 100,000 (4). Liver resection is the first line treatment for 
patients with localised, resectable tumours in the non-cirrhotic liver, or in selected patients with 
Child-Pugh A liver cirrhosis (5). It should be noted that with large tumours, or in the presence of 
cirrhosis, liver transplantation is often the preferred option. Outcomes of transplant in this setting 
are favourable, with 5- and 10-year survival rates reaching 62% and 51% respectively (6).  
 
Tumour free resection margins is vital for good outcomes, with R1 resection having been shown to 
be the only prognostic indicator precluding >10 years survival (7). A randomised trial compared 
survival outcomes of patients with narrow (1cm) and wide (2cm) resection margins; the 1-, 2-, 3-, 
and 5-year overall survival rates for the narrow and the wide margin groups were 92.9%, 83.3%, 
70.9%, and 49.1% and 96.5%, 91.8%, 86.9%, and 74.9%, respectively (8). Resection margin was a 
significant prognostic indicator for recurrence (OR 0.598), with all 13 recurrences at the transaction 
margin occurring within the narrow resection group. With careful selection of patients, 3-year and 5-
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year survival rates for complete, tumour free resection (R0) is 54% and 39% respectively, compared 
with 23% and 0% for R1-2 resections (9).  
 
Surgical resection of the liver is also vitally important for the management of colorectal cancer. 
Colorectal cancer rates have steadily increased in the UK since the late 1970s. In 2013, over 40,000 
patients were diagnosed with it, an incidence of over 70 per 100,000 (10). The liver is often the first 
site of metastasis, with around 20-25% of patients with liver metastases at diagnosis and half of all 
patients going on to develop them in their lifetime (11). Unfortunately, survival without treatment is 
poor and it has become increasingly recognised that surgical resection is the only chance for long-
term survival. This has been reflected in the increasing number of resections being performed in the 
UK, which rose from 1.7% in 1998, to 3.8% in 2004 (12). It is anticipated that 10-20% of patients with 
liver metastases have surgically resectable disease (13). This rise in resections is a direct result of the 
changing beliefs of what is considered resectable. Currently, surgically resectable disease is defined 
as the ability to perform R0 resection, sparing at least two liver segments with independent inflow, 
outflow and biliary drainage. The amount of the liver remnant after resection should not be less than 
20% and 30% of the total liver volume in normal and cirrhotic patients, respectively (14). Once 
surgical management has been decided upon, obtaining R0 resection, whilst preserving healthy 
tissue is key, with significantly worse outcomes if tumour extends past the resection margin (15). In 
both of these scenarios, identification of malignant versus healthy tissue is vital to achieve good 
outcomes. It was the advances in the use of FGS during assessment of coronary artery bypass grafts 
and identification of lymph node metastases (16–18) that led surgeons to experiment with 
fluorescence in liver malignancy.  
 
Fluorescence guided liver resections 
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Ishizawa et al.(18) published the first report detailing the use of ICG fluorescence to identify liver 
malignancy during resection.  Their investigation commenced as they noted that HCCs fluoresced 
when performing fluorescence guided intra-operative cholangiography during a previous study (20). 
The following prospective study involved 49 patients undergoing resection for liver malignancy (37 
HCC and 12 colorectal cancer liver metastases (CRLM)). All of the pathologically confirmed HCCs and 
CRLMs exhibited fluorescence when examined after resection.  Intra-operatively, fluorescence 
imaging identified 21 of the 41 (51%) of the HCCs examined and all of the CRLM present. No tumours 
at a depth greater than 8mm were identified. This is perhaps the most significant finding and is 
predictable as near-infrared (NIR) light penetrates human tissue to depths of 5-10mm (21). In one 
patient with HCC, fluorescence imaging of the specimen identified a large volume of residual 
malignancy, not identified by examination which required further resection. ICG is excreted by 
hepatocytes into the bile cannaliculi. It was surmised that liver malignancy, by disturbing biliary 
drainage, caused stasis and impaired excretion of ICG. As such, the malignancy fluoresced, whereas 
healthy tissue, having excreted ICG prior to the operation, does not.  
 (Insert figure 2) (22) 
 
These results were echoed by other studies published at the time. Gotoh et al. (23) reported the 
results of a similar study involving 10 patients with HCCs. Their case series contained 4 malignant 
lesions first identified by fluorescence. Ishizawa et al. continued their work investigating the 
prospects of ICG FGS, publishing works regarding delineating the biliary tree and liver segments 
using ICG. In 2014 the Tokyo based team revealed the first use of FGS during laparoscopic 
hepatectomy (24). NIR fluorescence identified 75% of HCCs and 69% of liver metastases in 17 
patients.   
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In the same year, Inoue et al. (25), published their use of 5-Aminolevulinic acid (5-ALA); a new 
fluorescent agent in Hepatobiliary surgery. Their aim was to establish whether 5-ALA fluorescence 
was advantageous as an adjunct to liver resection in 70 consecutive patients undergoing liver 
resection for HCC (n=37), CRLM (n=31), intraductal papillary carcinoma (n=1) and hemangiosarcoma 
(n=1). 342 patients who underwent liver resection between 2007 and 2011 were used as controls. 
HCC detection was similar during FGS and white light surgery; 64.9% versus 62.1% respectively. 
White light was marginally better detecting CRLM; 67.7% compared with 58.0% during FGS. It is not 
discussed whether identification of additional lesions by 5-ALA changed the operative course. There 
were no positive resection margins within the 5-ALA cohort, compared with 8 (2.3%) within the 
control group, this difference was not statistically significant. Whilst the primary outcome of lesion 
detection and resection margin is underwhelming, the frequency of post-operative complications is 
more significant. No patients experienced post-operative bile leak following FGS, compared with 19 
(5.2%) within the control group (p = 0.0548). 5-ALA is excreted into bile, leakage is therefore 
detectable under fluorescence imaging. During 5-ALA guided resection, 3 bile duct leaks were 
detected intra-operatively and subsequently repaired. This suggests 5-ALA may reduce the incidence 
of post-operative bile duct leakage. The question not asked by this study is whether 5-ALA may have 
additional benefits over ICG as a fluorescent marker. The authors suggest 5-ALA may have a lower 
false positive rate than ICG, however the data is not provided in this study. The tissue penetration of 
5-ALA fluorescence is far lower than when using ICG. This significantly hampers the effectiveness of 
5-ALA when directly comparing with ICG. 
 
Comparison with current gold standard intra-operative imaging 
Intra-operative ultrasound sonography (IOUS) is the gold standard intra-operative imaging technique 
during liver resections. IOUS was first trialled in 1981 (26) and has been shown to improve detection, 
characterisation and localisation of solid liver tumours during liver resection (27,28), with up to 30% 
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increase in lesion detection compared with pre-operative imaging (29). It was thought that due to 
the improvements in imaging technology that IOUS may be rendered obsolete, however recent 
studies have shown that IOUS continues to be vital during liver resection (32,33). In a series of 86 
consecutive patients undergoing liver resection for CRLM, pre-operative imaging identified 328 
lesions (32). IOUS identified an additional 31 lesions in 17 patients. Overall, IOUS changed the 
intended procedure in 29 (29.9%) cases, in 13 of these a larger resection was performed due to 
additional lesion detection; in 11 it reduced the resection due to improved lesion characterisation. 
Jrearz et al. found IOUS changed the pre-operative management plan in 17% of liver resections (33) 
and Schmidt et al. (34) have shown IOUS to have a sensitivity and specificity of 98% and 95% 
respectively for the detection of CRLM. With highly effective intra-operative imaging currently 
utilised, the value of FGS to guide liver resection is questionable. IOUS has a number of significant 
advantages over FGS, the most significant being its greatly increased tissue penetration. As stated 
previously, due to the nature of fluorescence, lesions greater than 10 mm deep remain undetected, 
there is no such restriction with IOUS. IOUS also has the additional benefit of further lesion 
characterisation. However, two areas of shortcomings of IOUS are that it cannot detect lesions 
<3mm in size and there is a superficial blind area 1 cm under the liver surface (35).  
 
Abo et al. aimed to further clarify the role of FGS in tumour detection and to compare its efficacy 
with intra-operative ultrasound sonography (IOUS) (36). The study comprised 117 patients due to 
undergo resection for Hepatobiliary tumours over a five year period at a single centre. Liver tumours 
included HCC, intrahepatic cholangiocarinoma, CRLM, as well as several others. All patients 
underwent IOUS followed by assessment under fluorescence imaging and lesions were resected as 
appropriate. IOUS diagnosed 109 of 111 malignant tumours and 5 of 6 benign tumours. Fluorescence 
imaging diagnosed 85 of the 111 malignant tumours and 3 of 6 of the benign tumours. The 
sensitivity and specificity of IOUS was 98% and 83% respectively, significantly greater than FGS had a 
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sensitivity of specificity of 77% and 50% respectively. The negative predictive value of IOUS was far 
higher, 71%, compared with 10% with FGS. The data (38) shows IOUS to be superior to fluorescence 
imaging in all measures of diagnostic precision, yet FGS may play a complimentary role with IOUS. In 
3 patients, additional deposits were identifiable only with FGS, it is not discussed whether this 
changed decision making during the operation or whether it resulted in further segmental resection. 
The two potential roles of fluorescence imaging that should be considered are inspection of the liver 
surface for lesions missed by IOUS and intra-operative examination of specimens to assess for clear 
resection margins. There is no data with regards to examination of resected specimens for a clear 
resection margin. Nor is there a discussion regarding the number of R0 or R1/R2 resections. There is 
also no data regarding survival or recurrence rates. This study contributes to the evidence that FGS 
should not replace IOUS during liver resection. Yet it does not fully explore its secondary outcomes. 
As such, conclusions with regards to the concomitant use of both IOUS and fluorescence imaging 
cannot be drawn. 
 
 
Hybridisation of fluorescence guided surgery and intra-operative ultrasound sonography 
Uchiyama et al. (37) first attempted to assess the effectiveness of concomitant use of contrast-
enhanced IOUS (CE-IOUS) and fluorescence imaging. 32 patients who were due to undergo liver 
resection for CRLM were enrolled within this prospective study. All patients underwent CT and MRI, 
as well as intra-operative CE-IOUS and examination under fluorescence imaging. Their findings are 
summarised, with two further studies in table 1.  Sensitivity (using pathology results as the gold 
standard) of CT/MRI was 88.5%, compared with 98.1% in CE-IOUS/FGS (p = 0.05). Positive predictive 
value (PPV) was comparable; CT/MRI – 95.8%, CE-IOUS/FGS – 96.3%. This small study demonstrates 
a small benefit for hybridisation. However, whilst two additional metastatic lesions were detected 
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under fluorescence, there were two additional false positives. CE-IOUS was highly sensitive and 
specific for lesions without the addition of fluorescence. Combining techniques added a little to the 
sensitivity however lowered the positive predictive value. The potential benefit of analysis of on-
table resection margins is not described, nor is data on R0 versus R1/R2 resections. This study does 
not provide data on post-operative outcomes, neither long nor short term. They also do not provide 
information regarding median operative time. Operative time is known to be a factor influencing 
outcomes post-operatively. This technique could potentially significantly lengthen operative time 
and thus negatively impact on outcomes.  
 
(Insert table 1)  
Peloso et al. (38) also hypothesised that IOUS could be used synergistically with fluorescence 
imaging to aid complete resection. 25 patients with CRLM underwent intra-operative IOUS and FGS.  
The results are summarised in table 1. IOUS detected 15 further lesions compared with CT, however 
the difference was not statistically significant (p=0.0708). Yet, when IOUS and fluorescence imaging 
were used concomitantly, lesion detection was significantly higher when compared with CT 
(p=0.0029). With tumours <3mm in size, the joint use of IOUS and fluorescence imaging resulted in 
significantly greater tumour detection rates than IOUS alone (p=0.0328). There were a total of 29 
lesions <3mm in size. 8 of these were identified pre-operatively, a further 7 were identified using 
IOUS and an additional 14 were identified using fluorescence imaging. A detailed account of the 
pathology reports is not provided but the authors do report one false positive lesion when using 
fluorescence imaging. The false positive rate is surprisingly low when compared with previous 
studies. The number of new lesions detected intra-operatively was dramatically higher than that 
described by Uchiyama et al. This could in part be explained by the difference in pre-operative 
imaging modality. Uchiyama et al. performed pre-operative CT and MRI; Peloso et al. used CT alone. 
Unlike Uchimaya et al., IOUS was not performed with the aid of contrast. As such, a number of 
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lesions detected by fluorescence imaging alone, may have been detected had CE-IOUS been used. 
Long term post-operative outcomes, including survival rates are not provided, however in all cases 
bar one, R0 resection was achieved. 
 
Van der Vorst  et al. (22) undertook a similar prospective study investigating the potential benefits of 
NIR fluorescence to guide liver resections in 40 patients from 2010 to 2012. Their results are 
summarised in table 1. Further resections were required in all five patients when additional lesions 
were detected by fluorescence imaging. One malignant lesion (confirmed by pathology), measuring 
9mm in diameter, was labelled a complicated cyst by both CT and IOUS and only identified as 
malignant under fluorescence imaging. Unsurprisingly, 26 lesions located >8mm from the surface 
were missed by NIR fluorescence.  
 
These three studies provide evidence that hybridisation of the two techniques increases tumour 
detection rate. By selecting only resections for CRLM a homogenous population is created, this 
allows greater ease of data interpretation and identifies a cohort where this technique may be 
effective. Yet their findings are not transferrable to resections for HCC. The differences in 
methodology between the studies are displayed in table 2. This may account for a number of the 
differences including, false positive rate, lesions detected only by NIR fluorescence and difference in 
pattern of fluorescence. 
(Insert table 2) 
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Translating preliminary trials into clinical results 
Before new techniques are incorporated into standard practice, a number of factors require 
consideration. First and foremost, clear evidence that it is better than, or comparable to current 
technology. The above data shows that IOUS rightly remains the gold-standard for intra-operative 
assessment of tumour deposition within the liver. The addition of fluorescence imaging may result in 
an increase in the detection of small, superficial metastatic deposits. Of particular interest, not 
commented on in the majority of trials is the intra-operative examination of resection margins under 
fluorescence. Clinical outcomes are also not addressed in the majority of trials. Inoue et al. (24) 
utilise a historical control group as a comparator and investigate post-operative outcomes between 
these cohorts. All other studies lack comparators and focus only on number of lesions detected.  A 
randomised control trial to investigate the efficacy of ICG fluorescence with IOUS compared with 
IOUS alone is justified. Patients should be followed up for R0 resection rates, median survival time 
and recurrence rates. This would provide a true evaluation of patient outcomes using this 
technology. 
 
A factor, noted throughout most studies is the presence of false positives. A number of benign 
lesions cause biliary stasis; therefore due the nature of FGS using ICG, the technique will always be 
subject to a number of inappropriate resections. 5-ALA may prove to have a higher specificity, yet 
the future lies in molecular targeting. Fluorescently labelled agents can be directed to adhere to 
certain cell surface antigens, or peptides displayed by tumour cells. Numerous pre-clinical trials have 
displayed the efficacy of targeting tumour specific antigens with fluorescent markers (39,40). 
Increasing the specificity of fluorescent markers will reduce the number of false positives identified 
during FGS, thus reducing the number of unnecessary resections and preserving normal liver 
parenchyma.  
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Fluorescence and the wider picture 
Clinical trials with live fluorescence, particularly in Hepatobiliary surgery, are clustered around 
certain academic institutions. Centres in Osaka, Nagasaki and Tokyo feature prominently in the 
literature. A significant proportion of the research has been performed by teams attached to the 
University of Tokyo, aided by numerous government grants (19,20,41,42). This is likely in part due to 
the health burden that HCC has in Japan compared with the rest of the world, driving research into 
liver resection. That the Photo Dynamic Eye imaging system is manufactured by Hammamatsu 
Phototonics, a technology firm based in Japan, may also play a role. The capital investments into this 
technology are not insignificant (46,000 US dollars (43)) and though no conflict of interest is 
declared, research incentives may have driven studies in this area. The team at Leiden University 
also provide significant contributions to the wider field of fluorescence in surgery (44). It is 
noticeable that some of their members are associated with the FLARE foundation, owners of the 
mini-FLARE technology. The initial cost of fluorescence devices may provide a disincentive to other 
institutions who would otherwise further research in this area. 
 
The cost of the technology should be considered not only in terms of guiding research, but also 
guiding clinical implementation. In health care systems such as the NHS a cost benefit analysis is 
performed before new technologies are introduced. Duggal et al. (45) performed an outcome 
analysis of intra-operative ICG angiography for postmastectomy breast reconstruction. Outcomes of 
184 patients that underwent the above procedure were compared to 184 historical controls, where 
ICG angiography was not performed. Rates of mastectomy skin necrosis and re-operation were 
significantly lower within the ICG angiography group; this resulted in a saving of 113,014 US dollars 
over the two years that this study was conducted. As yet, no cost benefit analysis for FGS in 
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Hepatobiliary surgery has been performed and with the advent of molecular targeting, this will 
almost certainly rise. When research is directed at outcomes following NIR fluorescence guided 
resections, the costs and potential savings will become more evident. This will increase uptake in 
systems, such as the NHS, where the opportunity cost must always be considered.  
 
 
Conclusion 
During hepatic resection, identification and removal of all malignant tissue is vital for prolonged 
patient survival. Fluorescence, due to its poor tissue penetration cannot detect deep liver lesions. As 
such, it has no role as the sole intra-operative imaging modality during liver resection. However, 
there is some evidence to suggest that hybridisation of IOUS and fluorescence imaging may increase 
tumour detection rate compared with IOUS alone. As yet, there is a paucity of evidence that shows 
this translates into improved patient outcomes. There is potential for FGS to reduce recurrence 
rates, by allowing the surgeon to assess the margin of resection intra-operatively and to detect 
further micro-metastatic deposits. To date, studies have not focused on R0 resection rates, 
recurrence rates and median survival time. Without robust patient outcome data, centres will be 
reluctant to invest in this relatively untested technology which requires significant start-up costs.  
The authors declare no conflict of interest. 
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Figure 2: NIR fluorescence of colorectal cancer liver metastases. (22) 
Figure 1 (2): The mechanism of NIR fluorescence imaging.  The agent is visualized using an NIR 
fluorescence imaging system. All systems must have adequate NIR excitation light, collection optics and a 
camera sensitive to NIR fluorescence emission light. The image displayed is a merging of the surgical field, 
displayed by white light, and the NIR fluorescence images. 
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Table 2: Hetrogeneity of studies 
 
 
 
 
 
  No. Additional lesions detected intraoperatively per imaging 
modality 
Study No. Lesions detected 
pre-operatively 
IOUS FGS 
Uchiyama et 
al. (39) 
46 3 2 
Peloso et al. 
(40) 
45 10 23 
Van der Vorst 
et al. (2013) 
73 19 5 
Table 1: Lesion detection of different imaging modalities between studies 
 Pre-operative 
imaging 
Ultrasound 
technique 
NIR imaging device 
Uchiyama et al. (2010) CT + MRI CE-IOUS Photo Dynamic Eye 
Peloso et al. (2013) CT IOUS Photo Dynamic Eye 
Van der Vorst et al. 
(2013) 
CT IOUS mini-FLARE 
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